REVB — Revelation Biosciences Income Statement
0.000.00%
Last trade - 00:00- $3.12m
- -$11.43m
Annual income statement for Revelation Biosciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K |
| Standards: | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | ||||
| Research And Development | ||||
| Total Operating Expenses | 2.53 | 12 | 10.9 | 8.66 |
| Operating Profit | -2.53 | -12 | -10.9 | -8.66 |
| Other Net Non Operating Costs | ||||
| Net Income Before Taxes | -2.53 | -12 | -10.8 | -0.12 |
| Net Income After Taxes | -2.53 | -12 | -10.8 | -0.12 |
| Net Income Before Extraordinary Items | ||||
| Net Income | -2.53 | -12 | -10.8 | -0.12 |
| Income Available to Common Shareholders Excluding Extraordinary Items | ||||
| Income Available to Common Shareholders Including Extraordinary Items | ||||
| Dilution Adjustment | ||||
| Diluted Net Income | -2.53 | -12 | -10.8 | -0.12 |
| Diluted Weighted Average Shares | ||||
| Basic EPS Including Extraordinary Items | ||||
| Diluted EPS Including Extraordinary Items | ||||
| Diluted EPS Excluding Extraordinary Items | ||||
| Normalised Income Before Taxes | ||||
| Normalised Income After Taxes | ||||
| Normalised Income Available to Common Shareholders | ||||
| Diluted Normalised EPS | -113 | -535 | -603 | -0.526 |
| Dividends per Share |